Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). (Q43515162)

24 November 2017

Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). (English)

1 reference

24 November 2017

Bialer M

1

1 reference

24 November 2017

Johannessen SI

2

1 reference

24 November 2017

Kupferberg HJ

3

1 reference

24 November 2017

Levy RH

4

1 reference

24 November 2017

Loiseau P

5

1 reference

24 November 2017

Perucca E

6

1 reference

24 November 2017

1 January 2001

1 reference

24 November 2017

1 reference

24 November 2017

43

1 reference

24 November 2017

1

1 reference

24 November 2017

11-58

1 reference

Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Guideline for prescribing vigabatrin in children has been revised. Vigabatrin Paediatric Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Topiramate relieves refractory intercostal neuralgia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Oxcarbazepine: pharmacokinetic interactions and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The disposition of valproyl glycinamide and valproyl glycine in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Topiramate as add-on treatment for patients with bipolar mania

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Enhanced recognition memory following vagus nerve stimulation in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Stable weight during lamotrigine therapy: a review of 32 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

An active-control trial of lamotrigine monotherapy for partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Progressive myoclonus epilepsy treated with zonisamide

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Retigabine strongly reduces repetitive firing in rat entorhinal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Sympathectomy alleviates mechanical allodynia in an experimental animal model for neuropathy in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Recovery of visual field constriction following discontinuation of vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Mutual interaction between remacemide hydrochloride and phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Safety of tiagabine: summary of 53 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Psychiatric adverse events during vigabatrin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Clinical pharmacology and pharmacokinetics of oxcarbazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Aspiration: a potential complication to vagus nerve stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Nonepileptic uses of gabapentin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Use of topiramate, a new anti-epileptic as a mood stabilizer.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Zonisamide: Pharmacology and Clinical Efficacy in Epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Rash in adult and pediatric patients treated with lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The anticonvulsant zonisamide scavenges free radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

1 reference

7 January 2021

Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Felbamate: 1997 update

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Is the devil we know the lesser of two evils? Vigabatrin and visual fields

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Chronic stimulation of the left vagal nerve in children: effect on swallowing

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Zonisamide monotherapy in newly diagnosed infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Ventricular asystole during vagus nerve stimulation for epilepsy in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Visual field constriction in children treated with vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Topiramate-treated cluster headache

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Characteristics of a unique visual field defect attributed to vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Factors Influencing the Incidence of Lamotrigine-Related Skin Rash

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Treatment of infantile spasms with zonisamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900171-6

7 January 2021

10.1016/S0920-1211(00)00171-6

Identifiers

DOI

1 reference

24 November 2017

1 reference